Infectious Disease
Acute Bronchitis
31
Pipeline Programs↗
2
Active Trials↗
10
Companies Involved↗
Acute bronchitis is a moderately active landscape with 31 programs across 10 companies. The most active players are Ahn-Gook Pharmaceuticals Co.,Ltd, Daewon Pharmaceutical Co., Ltd., Pfizer. 5 therapies are approved with 15 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 27
Phase 315
Analysis
Trial Status
20
clinical trials
Completed14 · 70%
Unknown status4 · 20%
Recruiting1 · 5%
Not yet recruiting1 · 5%
Clinical Trials
Trial Activity
20 trials
Effect of Ipratropium on Acute Bronchitis in Subjects Without Underlying Lung Disease
Completed·—·N/A·NCT00371527·200 enrolled
Evaluate the Efficacy and Safety of Acute Bronchitis Symptoms Improvement for Bronpass Tab. Compared to Erdos Capsule
Completed·—·Phase 4·NCT06038084·110 enrolled
Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.
Completed·FFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina·Phase 4·NCT03738917·668 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)